Chinese Biotech Firm Yingsheng Biology Gets $14M In Series C Round

For Digital Subscribers Only

Yingsheng Biology, a Chinese biotechnology firm that provides mass spectrometry (MS) services, announced on Wednesday that it has raised nearly RMB100 million (US$14.47 million) in a series C round of financing.

China Money Network

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech


Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!


Already have an account or paid subscription? Log in

China Expert network

RELATED NEWS



LEAVE A REPLY